NCT00442832View on ClinicalTrials.gov

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Staphylococcal Skin Infection
Interventions
DRUG

TD-1792

TD-1792 2 mg/kg/day IV

DRUG

Vancomycin

Vancomycin 1 Gm IV q 12 hrs

Trial Locations (1)

91950

Allan Churukian, National City

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY